Tvardi Therapeutics (TVRD) Long-Term Investments (2013 - 2023)

Tvardi Therapeutics has reported Long-Term Investments for 10 years, with the latest figure at $4.7 million in Q3 2023.

• Quarterly Long-Term Investments fell 80.15% year-over-year to $4.7 million in Q3 2023, while the trailing twelve-month figure through Sep 2023 was $4.7 million (down 80.15% YoY) and the FY2022 annual result came in at $11.4 million, down 83.73% from the prior year.
• Long-Term Investments fell to $4.7 million in Q3 2023 per TVRD's latest filing, from $7.1 million in the prior quarter.
• Over five years, Long-Term Investments peaked at $70.6 million in Q4 2020 and troughed at $4.7 million in Q3 2023.
• A 5-year average of $38.1 million and a median of $47.2 million in 2022 frame the typical range for Long-Term Investments.
• The sharpest annual moves came in 2021 and 2023: Long-Term Investments jumped 368.5% in 2021, then sank 86.74% in 2023.
• Over 5 years, Long-Term Investments stood at $63.2 million in 2019, then climbed by 11.73% to $70.6 million in 2020, then decreased by 1.15% to $69.8 million in 2021, then plunged by 83.73% to $11.4 million in 2022, then tumbled by 58.18% to $4.7 million in 2023.
• According to Business Quant data, Long-Term Investments over the past three periods registered $4.7 million, $7.1 million, and $9.1 million for Q3 2023, Q2 2023, and Q1 2023 respectively.